For the third fiscal quarter ended June 30, 2026, Outlook Therapeutics reported net loss attributable to common stockholders of $20.3 million, or $0.15 per basic and diluted share. This compares with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results